TrialPath

Find a study

Browse recruiting studies near you — free to check, always your choice.

Match me to a study

31 studies

Recruiting now, in plain language. Every study is watched over by an independent ethics board.

  • Eczema / atopic dermatitis

    A Study to Learn About Study Medicine Called PF-08049820 in People With Eczema

    Testing whether an experimental medicine is safe and works for eczema

    📍 Northridge Clinical Trials · Northridge, CA · +3 more US sites · Get directions →

    The purpose of this study is to learn if the study medicine (PF-08049820) is safe and effective for the treatment of atopic dermatitis (AD), also known as eczema, or atopic eczema. People with this condition may have severe itching and rashes on the skin.

    ✓ Study care freePhase 2Ages 18+Learn more →
  • Eczema / atopic dermatitis

    Cardamom and Topical Roseomonas in Atopic Dermatitis

    Testing cardamom and a skin-applied germ to treat eczema

    📍 National Institutes of Health Clinical Center · Bethesda, MD · Get directions →

    Background: Atopic dermatitis (AD), also called eczema, is a chronic skin condition. AD can make skin dry and itchy, and sometimes it can lead to serious health problems, such as asthma, food allergies, eye infections, and sleep problems.

    ✓ Study care freePhase 2Ages 2–100Learn more →
  • Eczema / atopic dermatitis

    A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis

    Testing the long-term safety and effects of a drug in people with eczema

    📍 Investigational Site · Fountain Valley, CA · +21 more US sites · Get directions →

    This is a multicenter, double-blind, Long-Term Extension (LTE) study to evaluate the long-term safety and efficacy of APG777 in patients with moderate-to-severe AD who have completed treatment in an APG777 Parent Study (NCT06395948). The LTE study will consist of 3 periods: 1) Screening Visit will coincide with the last visit of the Maintenance Period in the Parent Study 2) Extended Treatment Period 3) Post-treatment Follow-up Period.

    ✓ Study care freePhase 2Ages 18+Learn more →
  • Eczema / atopic dermatitis

    A Study Evaluating BFB759 in Moderate to Severe Atopic Dermatitis

    Testing a medicine for moderate to severe eczema, compared with a placebo

    📍 Mountain West Derm - Blackhart PLLC dba Skin Cancer and Dermatology Institute · Phoenix, AZ · +39 more US sites · Get directions →

    This is a double-blind, placebo-controlled study where subjects are participating for approximately 36 to 40 weeks. The study compares how well BFB759 works and how safe it is compared with a placebo.

    ✓ Study care freePhase 2Ages 18–75Learn more →
  • Heart / cardiovascular disease

    Improving Coronary Vascular Health in Women

    Testing whether blood flow in heart arteries can be improved in women with HIV

    📍 Massachusetts General Hospital · Boston, MA · Get directions →

    Women with HIV have an increased risk of having a myocardial infarction (heart attack) as compared to women without HIV. One of the mechanisms underlying the increased risk of myocardial infarction among women with HIV may involve reduced ability to increase blood flow through large and small coronary arteries at times when increased flow of oxygen-carrying blood is needed.

    ✓ Study care freePhase 2Ages 45–75WomenLearn more →
  • Eczema / atopic dermatitis

    A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis

    Testing different doses of a medicine versus placebo for eczema

    📍 Inmagene Site 1 · Lancaster, CA · +14 more US sites · Get directions →

    The purpose of this study is to evaluate the efficacy and safety of different dose regimens of IMG-007, compared to placebo.

    ✓ Study care freePhase 2Ages 18–74Learn more →
  • Eczema / atopic dermatitis

    Study to Evaluate Soquelitinib in Participants With Moderate to Severe AD

    Testing how different doses of soquelitinib work for moderate to severe atopic dermatitis

    📍 Corvus Clinical Trials · South San Francisco, CA · Get directions →

    The main purpose of this study is to see how well different doses of soquelitinib work in participants with atopic dermatitis (AD) as compared to a placebo (pill with no medicine in it). To check this, the study doctors will examine participants' skin regularly to track how their AD changes during the study.

    ✓ Study care freePhase 2Ages 18+Learn more →
  • Eczema / atopic dermatitis

    Treatment of Atopic Dermatitis and Alopecia Areata With Abrocitinib in Individuals With Down Syndrome

    Testing a daily medicine for eczema and hair loss in people with Down syndrome

    📍 Icahn School of Medicine at Mount Sinai · New York, NY · Get directions →

    This is a single-center, open-label, basket phase 2b trial that will enroll Down Syndrome (DS) participants with at least one inflammatory skin condition (Atopic Dermatitis (AD) and/or Alopecia Areata (AA)). Patients will receive Abrocitinib 100 mg daily for 12 weeks.

    ✓ Study care freePhase 2Ages 12+Learn more →
  • Eczema / atopic dermatitis

    A Long Term Extension Study to Evaluate the Safety and Efficacy of Afimkibart (RO7790121) in Participants With Atopic Dermatitis

    Checking the long-term safety and effects of an eczema medicine in people who previously studied it

    📍 Hamilton Research, LLC · Alpharetta, GA · +2 more US sites · Get directions →

    This study will assess long-term safety and efficacy of Afimkibart (also known as RO7790121) in participants with Atopic Dermatitis (AD) who participated in previous afimkibart clinical trials.

    ✓ Study care freePhase 2Ages 18+Learn more →
  • Heart / cardiovascular diseaseLupus (SLE)

    The Role of Anifrolumab in Improving Markers of Vascular Risk in Patients With Systemic Lupus Erythematosus (SLE) - IFN-CVD

    Testing whether anifrolumab improves blood vessel risk markers in lupus

    📍 National Institutes of Health Clinical Center · Bethesda, MD · Get directions →

    Background: People with systemic lupus erythematosus (SLE) are at risk of developing complications in their blood vessels. This can increase the risk of heart attacks or stroke.

    ✓ Study care freePhase 2Ages 18–80Learn more →
  • Eczema / atopic dermatitis

    A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis

    Testing how camoteskimab works in adults with moderate to severe eczema

    📍 AllerVie Clinical Research · Birmingham, AL · +32 more US sites · Get directions →

    This is a phase 2b, multicenter, randomized, double-blind, placebo-controlled study.

    ✓ Study care freePhase 2Ages 18–65Learn more →
  • Eczema / atopic dermatitis

    📍 Physioseq, LLC /ID# 267266 · Sacramento, CA · +1 more US site · Get directions →

    Hidradenitis suppurativa (HS) and atopic dermatitis (AD) are chronic inflammatory skin diseases that lead to the development of skin lesions and symptoms such as pain and discomfort. The purpose of this study is to assess molecular changes in adult participants with moderate to severe HS or with moderate to severe AD.

    ✓ Study care freePhase 2Ages 18–75Learn more →
  • Eczema / atopic dermatitis

    Evaluate Efficacy and Safety of Repeat Subcutaneous Doses of FB825 in Adults With Moderate-to-Severe Atopic Dermatitis

    Testing repeat under-the-skin doses of FB825 for adult eczema

    📍 First OC Dermatology · Fountain Valley, CA · +5 more US sites · Get directions →

    This is a randomized, placebo-controlled and double-blind study to evaluate the efficacy, pharmacokinetics, and Safety of repeat subcutaneous doses of FB825 in adults with moderate-to-severe atopic dermatitis.

    ✓ Study care freePhase 2Ages 18–65Learn more →
  • Eczema / atopic dermatitis

    📍 ALS Global · Irving, TX · Get directions →

    This is a Phase 2, randomized, double-blind, vehicle-controlled clinical study evaluating the efficacy and safety of GX-03 topical ointment in adult subjects with moderate to severe atopic dermatitis (eczema). The study plans to enroll up to 120 eligible patients with a target of at least 100 completing the study and an ability to expand enrollment up to 200 subjects based on a pre-specified interim assessment conducted by an Independent Data Monitoring Committee (IDMC).

    ✓ Study care freePhase 2Ages 18–80Learn more →
  • High cholesterol

    A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemia

    Testing how safe and well weekly injections of alirocumab work for high cholesterol in adults

    📍 Anaheim Clinical Trials · Anaheim, CA · +29 more US sites · Get directions →

    This study is researching an experimental drug called alirocumab, referred to as "study drug". In the United States, alirocumab is approved for the treatment of hypercholesterolemia (high blood cholesterol levels).

    ✓ Study care freePhase 2Ages 18–80Learn more →
  • Obesity / overweightHeart / cardiovascular disease

    A Phase 2 Study to Evaluate the Pharmacodynamics, Safety and Tolerability of BGE-102 in Participants With Obesity and Cardiovascular Risk Factors

    Testing how BGE-102 affects inflammation blood tests and safety in people with obesity and heart

    📍 Site 108 · Chandler, AZ · +11 more US sites · Get directions →

    The purpose of this study is to learn about the effects of BGE-102 on blood biomarkers including hsCRP, which is a lab value used to measure inflammation. BGE-102 decreases inflammation which may improve obesity and cardiovascular health.

    ✓ Study care freePhase 2Ages 18+Learn more →
  • Obesity / overweightHeart / cardiovascular disease

    Mechanisms of Semaglutide Therapy in Heart Failure Patients

    Testing how semaglutide works in people with heart failure and obesity

    📍 Greenstone Biosciences · Palo Alto, CA · +1 more US site · Get directions →

    Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist, primarily used for treatment of type-2 diabetes mellitus. GLP-1 receptors are present on pancreatic islet β-cells, δ-cells and α-cells.

    ✓ Study care freePhase 1Ages 20–80Learn more →
  • Heart / cardiovascular disease

    Canagliflozin Targeting Vascular Inflammation

    Testing canagliflozin to reduce blood vessel inflammation in cardiovascular disease

    💵 May compensate

    📍 University of Ottawa Heart Institute · Ottawa, Ontario · Get directions →

    CANTOR SING is a pilot single center double blinded randomized study. The investigators will compare the effect of canagliflozin (300 mg daily - intervention arm) vs.

    ✓ Study care freePhase 2Ages 18+Learn more →
  • Heart / cardiovascular disease

    Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)

    Testing a medicine to see its cardiovascular effects in adults on dialysis

    📍 Nephrology of North Alabama · Decatur, AL · +39 more US sites · Get directions →

    This is a two-part, phase 2b and phase 3 combined prospective, interventional, multicenter, randomized, double-blind, placebo-controlled study. Part 1: Phase 2b is a dose-finding study for CSL300 vs placebo.

    ✓ Study care freePhase 2Ages 18+Learn more →
  • Eczema / atopic dermatitis

    📍 Atd002 52021 · Oceanside, CA · +19 more US sites · Get directions →

    The purpose of the study is to evaluate the dose-response relationship of galvokimig compared with placebo in study participants with moderate-to-severe atopic dermatitis (AtD).

    ✓ Study care freePhase 2Ages 18+Learn more →
  • Eczema / atopic dermatitis

    Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis

    Testing a daily medicine for eczema severity in adults over 12 weeks

    📍 Enveda Investigative Site · Birmingham, AL · +22 more US sites · Get directions →

    The goal of this clinical trial is to learn about the safety and effectiveness of ENV-294 in adults with moderate to severe atopic dermatitis. The main questions it will answer are: * Is there an impact on the severity and area of atopic dermatitis when participants take ENV-294 * What medical problems do participants have when taking ENV-294 Participants will: * Take drug ENV-294 or a placebo once every day for 12 weeks * Visit the clinic every 2 to 4 weeks for checkups and tests * Keep a diary of their symptoms and when they took their study drug * Return to the clinic for the final study visit at approximately week 16

    ✓ Study care freePhase 2Ages 18–75Learn more →
  • Eczema / atopic dermatitis

    A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis

    Testing two medicines for safety and effects in people with eczema

    📍 Allervie Clinical Research · Birmingham, AL · +39 more US sites · Get directions →

    The purpose of this study is to learn about the safety and effects of 2 study medicines (PF-07275315 and PF-07264660) for the treatment of atopic dermatitis (AD). AD is a long- lasting itchy red rash, caused by a skin reaction.

    ✓ Study care freePhase 2Ages 18+Learn more →
  • Eczema / atopic dermatitis

    Effects of Treatments on Atopic Dermatitis

    Testing treatments for eczema (atopic dermatitis)

    📍 National Institutes of Health Clinical Center · Bethesda, MD · Get directions →

    Background: \- Atopic dermatitis, or eczema, is a chronic skin disorder. Patients sometimes have infections with S.

    ✓ Study care freePhase 2Ages 2–50Learn more →
  • High cholesterolLupus (SLE)

    IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy

    Testing certolizumab added to usual treatment to improve pregnancy in lupus and antiphospholipid

    📍 Hospital for Special Surgery · New York, NY · +1 more US site · Get directions →

    This treatment trial evaluates the addition of an anti-tumor necrosis factor-alpha drug, certolizumab, to usual treatment (a heparin agent and low-dose aspirin) in pregnant women with antiphospholipid syndrome (APS) and repeatedly positive tests for lupus anticoagulant (LAC) to determine if this regimen will improve pregnancy outcomes. All enrolled patients will receive certolizumab, and pregnancy outcomes will be compared to those of women with APS and repeatedly positive tests for LAC enrolled in a previous study by the investigators.

    ✓ Study care freePhase 2Ages 18–40WomenLearn more →
  • Heart / cardiovascular disease

    Ertugliflozin in Chronic Heart Failure

    Testing ertugliflozin and other medicines for heart failure symptoms

    📍 Yale School of Medicine · New Haven, CT · Get directions →

    The purpose of this study is to determine the effects on heart failure signs and symptoms of the use of either ertugliflozin, metolazone or placebo, in conjunction with intravenous loop diuretic use in acute settings and chronic oral loop diuretic therapy. There are two general purposes for this study.

    ✓ Study care freePhase 2Ages 18+Learn more →
  • Heart / cardiovascular disease

    Mesenchymal Stem Cells for the Treatment of Various Chronic and Acute Conditions

    Testing stem cell treatment for safety and effects on heart disease

    📍 Southern California Hospital at Culver City / Southern California Hospital at Hollywood / Multiple US-based Sub-Investigator Sites · Culver City, CA · Get directions →

    This multi-arm, multi-site study investigates the safety, tolerability, and efficacy of stem cell therapy for the treatment of various acute and chronic conditions. Clinically observed initial findings and an extensive body of research indicate regenerative treatments are both safe and effective for the treatment of multiple conditions.

    ✓ Study care freePhase 1Ages 18+Learn more →
  • Heart / cardiovascular diseaseHigh blood pressure

    Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)

    Studying how vitamin C affects blood vessel function in obese adults with insulin resistance and

    📍 University of Kansas Medical Center · Kansas City, KS · Get directions →

    The main purpose of research is to examine and understanding the development of hypertension in obese adults with insulin resistance. Findings from our studies will identify unique mechanisms that can be targeted to limit increases in vascular dysfunction and reduce the excessively high prevalence of hypertension and risk for cardiovascular disease (CVD).

    ✓ Study care freePhase 1Ages 35–65Learn more →
  • Obesity / overweightHeart / cardiovascular diseaseHigh blood pressure

    PRECISION-BP: Precision Chronopharamacotherapy Targeting NP-RAAS-BP Rhythm Axis

    Testing timing of blood pressure medicines in people with obesity and high blood pressure

    📍 University of Alabama at Birmingham · Birmingham, AL · Get directions →

    Obese individuals have a higher prevalence of nocturnal hypertension and non-dipping blood pressure (BP). These conditions are associated with an increased risk of cardiovascular (CV) events and death.

    ✓ Study care freePhase 2Ages 18+Learn more →
  • Heart / cardiovascular diseaseKidney disease

    Effect of Dapagliflozin on Metabolomics and Cardiac Mechanics in Chronic Kidney Disease

    Testing dapagliflozin with standard care on heart and lung function and blood metabolites in chronic

    📍 Northwestern University · Chicago, IL · Get directions →

    The goal of this study is to better understand the effects of a sodium-glucose transport protein 2 inhibitor, dapagliflozin, added on to standard of care on heart and lung function and circulating metabolites (substances created when our bodies break down food, drugs, or its own tissues) in patients with chronic kidney disease.

    ✓ Study care freePhase 1Ages 18–85Learn more →
  • Obesity / overweightHeart / cardiovascular disease

    Effects of Tirzepatide on Muscle and Vascular Health in Obese Older Adults

    Testing tirzepatide to see effects on muscle and blood vessels in older adults with obesity and

    📍 University of Texas Health Science Center at San Antonio · San Antonio, TX · Get directions →

    Obesity and type 2 diabetes mellitus (T2DM) represent major public health concerns in the aging community. Tirzepatide, a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist recently approved for the treatment of T2DM and obesity has been shown to be effective at reducing weight, improving markers of T2DM control, and improving cardiovascular health.

    ✓ Study care freePhase 2Ages 50+Learn more →
  • Eczema / atopic dermatitis

    Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis

    Testing medicines for safety and how well they work for moderate to severe eczema

    📍 Novartis Investigative Site · Birmingham, AL · +21 more US sites · Get directions →

    This trial is designed to evaluate multiple compounds in participants with moderate to severe atopic dermatitis (AD).

    ✓ Study care freePhase 2Ages 18–100Learn more →